Anderson J, Struthers A, Christofides N, Bloom S
Clin Sci (Lond). 1986 Apr;70(4):327-31. doi: 10.1042/cs0700327.
For many years experimental evidence has suggested the existence of a circulating factor able to enhance sodium excretion. Very recently peptides with natriuretic activity in experimental animals have been isolated from mammalian and human cardiac tissue. In order to determine whether this natriuretic activity has relevance to man we have studied the effects of an infusion of alpha-human atrial natriuretic peptide (alpha-h-ANP) in normal subjects. Sodium excretion trebled (P = less than 0.005) during the infusion of a calculated dose of 15 pmol of alpha-h-ANP min-1 kg-1 and there was an accompanying diuresis; radioimmunoassay of plasma alpha-h-ANP during the natriuresis indicated a mean peak incremental concentration of 203 +/- 78 (SEM) pmol/l. The infusion of a calculated dose of 1.5 pmol min-1 kg-1 did not affect sodium excretion. There were no haemodynamic changes and no side effects were noted.
多年来,实验证据表明存在一种能够增强钠排泄的循环因子。最近,已从哺乳动物和人类心脏组织中分离出在实验动物中具有利钠活性的肽。为了确定这种利钠活性是否与人类相关,我们研究了向正常受试者输注α-人心房利钠肽(α-h-ANP)的效果。在以15 pmol·min⁻¹·kg⁻¹的计算剂量输注α-h-ANP期间,钠排泄量增加了两倍(P<0.005),同时伴有利尿作用;利钠过程中血浆α-h-ANP的放射免疫测定表明平均峰值增量浓度为203±78(SEM)pmol/L。以1.5 pmol·min⁻¹·kg⁻¹的计算剂量输注对钠排泄没有影响。未观察到血流动力学变化,也未发现副作用。